Intercept discloses cardiovascular events reported in a study of the company's fatty liver disease drug.
Gilead has transformed itself with tremendous success twice already and is now working on plan number three.
Richard Pearson's expose, published yesterday on Seeking Alpha, pulls back the curtain on the shady world of paid stock touts. It's an excellent, well-researched story, mostly because of the documentation (emails and electronic signatures) Pearson obtained linking executives at Cytrx and Galena Biopharma to the publication of promotional articles under assumed names and without proper financial disclosure.
Northwest Bio: A German Translation Ate My DCVax Press Release
The FDA's clinical hold placed on Geron's imetelstat means all clinical trials are suspended.
A combination of Oxigene's Zybrestat and Roche's Avastin delayed the regrowth of tumors in women with advanced ovarian cancer.
Northwest Bio received good news from Germany in February but didn't tell investors until Monday.
Investors in a biotech stock bubble whistle past legitimate concerns about La Jolla's GCS-100.
A closer look at the interim analyses for two cancer vaccine trials reveals potential problems.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.